Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. Issue 2 (3rd October 2017)

• Record Type: Journal Article
• Authors: Kurozumi, Akira; Okada, Yosuke; Arao, Tadashi; Kobayashi, Takuya; Masuda, Daisaku; Yamashita, Shizuya; Tanaka, Yoshiya
• Is Part Of: Journal of diabetes investigation. Volume 9:Issue 2(2018)
• Page Start: 360
• Page End: 365
• Publication Date: 2017-10-03
• Subjects: Apolipoprotein B‐100 -- Dipeptidyl peptidase 4 inhibitor -- Type 2 diabetes mellitus; Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.12739
• Languages: English
• ISSNs: 2040-1116

Abstract

Abstract: Introduction: Anagliptin (ANA) improves dyslipidemia in addition to blood glucose levels. However, there are no comparative studies on the effects of ANA and other dipeptidyl peptidase‐4 inhibitors on serum lipid profile. We compared the effects of ANA on serum lipid profile with those of alogliptin (ALO) in type 2 diabetes mellitus outpatients. Materials and Methods: The study participants were 87 type 2 diabetes mellitus patients who had been treated with dipeptidyl peptidase‐4 inhibitors for ≥8 weeks and had a low‐density lipoprotein cholesterol (LDL‐C) level of ≥120 mg/dL. Participants were switched to either 200 mg/day ANA or 25 mg/day ALO for 24 weeks. Results: There was no significant difference in percentage change in LDL‐C level at 24 weeks between the ANA and ALO groups. Treatment with ANA for 12 weeks significantly decreased LDL‐C levels, one of the secondary end‐points. Treatment with ANA for 24 weeks significantly improved apolipoprotein B‐100 levels, and the percentage change in LDL‐C levels at 24 weeks correlated significantly with the percentage change in apolipoprotein B‐100 levels in the ANA group. Conclusions: The LDL‐C‐lowering effects of ANA and ALO at 24 weeks were almost similar in patients with type 2 diabetes mellitus. However, the results showed a tendency for a decrease in LDL‐C level at 24 weeks in the ANA group, and that such improvement was mediated, at least in part, through the suppression of apolipoprotein B‐100 synthesis. Abstract : The randomized, parallel‐group study demonstrated that when patients previously treated with a DPP4 inhibitor were switched to anagliptin, a tendency for a decrease in LDL‐C level at 24 weeks in the Anagliptin group, and that such improvement was mediated, at least in part, through the suppression of apoB‐100 synthesis. We believe our study is rare, interest and this is the first clinical study to suggest the mechanism underlying the ameliorating effect of anagliptin on LDL‐C levels.